VIDEO: Aflibercept 8 mg may decrease treatment burden in wet AMD
Click Here to Manage Email Alerts
SEATTLE — In this video, Esther M. Bowie, MD, discusses the results of the phase 3 PULSAR trial presented at the ASRS annual meeting.
The trial compared the efficacy of aflibercept 8 mg, recently approved as Eylea HD, administered every 12 weeks or 16 weeks vs. aflibercept 2 mg every 8 weeks for the treatment of neovascular age-related macular degeneration.
The majority of patients were able to maintain noninferior visual acuity through the 12-week and 16-week intervals, according to Bowie, a professor of ophthalmology at the Penn State Health Milton S. Hershey Medical Center.
“We have good treatments, but we have to inject them every month, every 2 months, and that’s tough for patients,” Bowie said.
Reference:
- Patel J. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the phase 3 PULSAR trial. Presented at: American Society of Retina Specialists annual meeting; July 28-Aug. 1, 2023; Seattle.
Collapse
Healio Interviews
Click Here to Manage Email Alerts